NewsRoom Articles - Page 73 of 154 - PsychedelicNewsWire (PNW)

FridayJan 07, 2022 1:38 pm

A Recap of How Psychedelics Fared in 2021

At the start of last year, only a few psychedelic companies were trading on the exchange markets, with Compass Pathways (NASDAQ: CMPS) and Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (“MindMed”) among them. However, this year saw a number of IPOs, which increased the total number of public psychedelic companies trading on the market. These companies include Atai Life Sciences (NASDAQ: ATAI), Field Trip Health (NASDAQ: FTRP) and Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF). This increase brought more resources to the space, which helped ensure its survival. In addition, it widened the scope of treatments being researched as well as the…

FridayJan 07, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Signs LOI with Maya to Co-Develop a Prescription Digital Therapeutics Platform Targeting a Trifecta Approach to Patient Care

Mydecine has signed a letter of intent with Maya detailing a collaborative partnership to develop a novel digital therapeutics (“DTx”) platform The DTx platform is expected to create a three-pronged approach to patient care by combining Mydecine’s Mindleap digital health platform with its medication-based treatments According to COO Damon Michaels, the new platform will provide improved adherence to treatment protocols, patient experience, biometric insights, and post-approval insurance reimbursements Both companies intend to pursue rigorous studies to achieve FDA clearance Regarded as the convergence of health care and software that has resulted in a new crop of life sciences technology helping…

ThursdayJan 06, 2022 12:00 pm

Clinical Psychologists Cautiously Evaluating Psychedelic-Backed Mental Health Treatment

A new survey has found that mental health professionals believe that psychedelic substances possess psychological benefits. This was despite concerns about the potential neurocognitive and psychiatric risks linked to using psychedelic treatment. Gabrielle Agin-Liebes, the author of the study, stated that while there was a lot of interest in the potential use of psychedelics in clinical care, there also existed a lot of negative attitudes toward psychedelic therapy. She explained that understanding the extent to which psychedelic treatments would be accepted in the healthcare system would help advance the clinical use of these drugs once they received approval for medical…

ThursdayJan 06, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key Meeting with UK Regulatory Agency

Meeting takes company a step closer to advancing its lead investigational candidate CYB003 into clinical development CYB003 is designed for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”) CEO notes that CYB003 has the potential to achieve better patient outcomes The coming year holds significant promise for Cybin (NEO: CYBN) (NYSE American: CYBN) for numerous reasons. The biopharmaceutical company has seen significant success in the execution of its strategic focus on progressing psychedelics to therapeutics, including its recent announcement that company representatives will hold a scientific advice meeting with the UK Medical and Healthcare…

WednesdayJan 05, 2022 1:45 pm

Study Finds Psilocybin-Assisted Psychotherapy Effective in Treating Suicidal Ideation in Cancer Patients

Patients with cancer have a high risk of suicidal ideation and suicide, in particular patients in the advanced stages. These individuals often experience a loss of meaning in life and existential distress, which isn’t easily remedied through the use of pharmacological treatments. However, a new study has found that psilocybin when used together with psychotherapy may alleviate suicidal ideation in patients with life-threatening cancers. The improvements observed in patient mental health were maintained months and even years after treatment had been administered. The study’s findings were reported in the “ACS Pharmacology & Translational Science” journal. The researchers, led by Stephen…

WednesdayJan 05, 2022 11:53 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Entering 2022 With Multiple Clinical Trials Including MYCO-001 for Smoking Cessation

Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University for two upcoming trials for MYCO-001 – a psilocybin approach to smoking cessation The company is positioned to fill a billion-dollar hole in the industry after the leading pharmaceutical Chantix was removed from the market due to cancer risks Two previous psilocybin trials conducted by Dr. Johnson, show promising results for the use of psilocybin as a smoking cessation tool when paired with cognitive behavioral therapy (“CBT”) Smoking remains among the leading public health concerns of the 21st century. The total number of tobacco-related deaths worldwide has reached six…

TuesdayJan 04, 2022 2:48 pm

Study Finds That Psilocybin’s Therapeutic Effect Isn’t Altered by SSRI Medication

Compass Pathways recently released data that shows that selective serotonin reuptake inhibitor (“SSRI”) drugs can be used together with psilocybin. SSRI drugs are commonly used to treat mental health conditions including anxiety and depression. Estimates show that more than 300 million individuals globally suffer from major depressive disorder, with about one-third of that population not getting finding any help or relief from current therapies. Compass is carrying out a trial for its COMP360 psilocybin formulation, which involves patients on SSRI therapy being administered with one 25 mg dose of its therapeutic formulation. The study found that the treatment outcomes in…

TuesdayJan 04, 2022 10:39 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance for Revolutionary Treatment of Anxiety Disorders

USPTO notice marks important milestone in the expansion of CYBN’s intellectual property portfolio Once issued, patent may have opportunity to cover a broad range of claims Anxiety disorders are one of the most common mental illnesses in the United States Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its commitment to progressing Psychedelics to Therapeutics(TM). The biopharmaceutical company has received a notice of allowance from the U.S. Patent and Trademark Office (“USPTO”) in regard to its patent application connected to its investigational deuterated psychedelic tryptamine compound for the potential treatment of anxiety disorders (https://ibn.fm/fpjXm). “The receipt of…

MondayJan 03, 2022 1:20 pm

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO Joins Gamechangers LIVE Podcast; Shares Views on the Evolution of the Psychedelics Industry

Delic Corp is a leading psychedelic wellness platform with a business network which includes psychedelic wellness clinics, psilocybin research facilities, a famed psychedelic wellness event, and dedicated media and e-commerce platforms Delic’s CEO, Matt Stang recently joined the Gamechangers LIVE podcast to share his perspective on the development of the psychedelic industry along with Delic’s commercial evolution Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leading psychedelic wellness platform committed to bringing science-backed benefits to its many stakeholders, has long been known for its role as a trailblazer of new medicines and treatments in the current environment. Its goal is to…

ThursdayDec 30, 2021 3:45 pm

Washington City Approves Measure to Decriminalize Psychedelic Substances

Last week, the city of Port Townsend became the latest city to decriminalize entheogenic fungi and plants through a measure that was unanimously adopted by the city council of Port Townsend. This Washington State city is the latest city to relax its policy on psychedelic substances. Under the approved measure, laws against natural psychedelic plants including ayahuasca, peyote and magic mushrooms, will be the lowest priority for law enforcement in the city. Natural psychedelic substances are sometimes referred to as entheogenic fungi and plants. The initiative also conveys support for the decriminalization of psychedelic drugs at the federal level. In…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000